Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
GSK taps a startup for shot at Alzheimer’s drug | BioPharma Dive
Dec 5, 2024 · Inside every human cell are thousands of snippets of genetic code that serve as the directions for creating proteins. And over the past four years, a small biotechnology company has been trying to prove that, by looking closely enough at this assembly of instructions, it can find new ways to treat diseases like Alzheimer’s, Parkinson’s and multiple sclerosis.
Merck targets 2025 RSV season with antibody now under FDA review
Dec 17, 2024 · Dive Insight: There are currently several ways to protect children from RSV. Beyfortus can be used in infants who are entering their first or second RSV season, while Pfizer’s vaccine Abrysvo can be given to pregnant women to pass on passive immunity to their newborns.
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · A guidance from the U.S. FDA (draft updated in March 2020) requires data on cardiovascular events in new T2D drug development programs.As a result, dedicated cardiovascular safety trials were implemented. Many demonstrated beneficial effects of GLP-1 RAs on the heart and kidneys in patients with T2D (with and without preexisting conditions), …
Sanofi, Teva say study results show gut disease drug could be …
Dec 17, 2024 · Dive Brief: An experimental drug co-developed by Teva and Sanofi met its main objectives in a mid-stage clinical trial in inflammatory bowel disease, showing what the partners claimed to be “best-in-class potential.”; Around half of people with ulcerative colitis who received a high dose of the drug, duvakitug, in a Phase 2 trial had their symptoms resolve after 14 weeks, …
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
Merck calls quits on two immunotherapies for cancer
Merck & Co. on Dec. 16, 2024, cancelled work on combination therapies with its cancer drug Keytruda. Sundry Photography via Getty Images
An RNAi renaissance is creating a new generation of startups
Nov 6, 2024 · A new group of startups, though, believes RNAi is ready to take another big leap forward. Backed by experienced and high-powered investors, they say the necessary technical advances have been made to significantly expand use of the technology.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22, 2024 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day …
Roche’s Xofluza reduces flu transmission in Phase 3 study
Sep 19, 2024 · Dive Brief: Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company said Wednesday.; Treatment with a single dose of Xofluza within 48 hours of symptom onset lowered the likelihood an infected person passed on the virus to other individuals within the same household.